title: Amgen's point of view on epoetins.
authors.affiliation: Global Development, Amgen, Thousand Oaks, CA, USA.
authors.forename: Beth
authors.initials: B
authors.lastname: Seidenberg
authors.forename: Roger M
authors.initials: RM
authors.lastname: Perlmutter
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D018450:Disease Progression; D004345:Drug Industry; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use*; D006291:Health Policy; D006397:Hematinics / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D040541:Marketing; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012449:Safety; D012955:Societies, Medical; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D006397:Hematinics; D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin; D000068817:Epoetin Alfa